monomethyl fumarate
Commercial- Indications
- Relapsing multiple sclerosis
Company intelligence / Profile preview
Banner Life Sciences
High Point, North Carolina, United Statesbannerls.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Banner Life Sciences has developed BAFIERTAM® (monomethyl fumarate), an FDA-approved disease-modifying therapy for relapsing forms of multiple sclerosis. The company leverages proprietary formulation expertise to address unmet clinical needs, with a focus on improving gastrointestinal tolerability and patient outcomes
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules (notably monomethyl fumarate)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Banner Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Banner Life Sciences.